Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $34.57

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have earned a consensus rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $34.57.

Several analysts have commented on DAWN shares. HC Wainwright decreased their target price on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Wedbush reiterated an “outperform” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lowered their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Finally, The Goldman Sachs Group lowered their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, February 10th.

Day One Biopharmaceuticals Price Performance

NASDAQ:DAWN opened at $8.79 on Friday. The stock’s 50-day moving average is $11.52 and its two-hundred day moving average is $13.09. The stock has a market cap of $890.91 million, a PE ratio of -8.53 and a beta of -1.38. Day One Biopharmaceuticals has a fifty-two week low of $7.88 and a fifty-two week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The business had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. On average, equities research analysts anticipate that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Charles N. York II sold 4,370 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the sale, the chief financial officer now directly owns 252,638 shares of the company’s stock, valued at $3,021,550.48. This represents a 1.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock worth $251,925 over the last three months. 8.40% of the stock is currently owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Day One Biopharmaceuticals during the fourth quarter worth $27,000. R Squared Ltd acquired a new stake in Day One Biopharmaceuticals during the fourth quarter worth approximately $31,000. Quest Partners LLC grew its stake in Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after buying an additional 7,668 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Day One Biopharmaceuticals by 911.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after purchasing an additional 9,603 shares during the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in Day One Biopharmaceuticals in the fourth quarter valued at about $143,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.